The therapeutic potential of targeting the cell cycle.
暂无分享,去创建一个
[1] E. Sausville,et al. Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol , 1998 .
[2] Y. Nouvian‐Dooghe,et al. Human cyclin B1 is targeted to the nucleus in G1 phase prior to its accumulation in the cytoplasm. , 1996, Oncogene.
[3] S. Bursell,et al. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.
[4] E. Lees,et al. Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. , 1996, Oncogene.
[5] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[6] F. Lallemand,et al. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. , 1997, Anti-cancer drugs.
[7] H. Yokozaki,et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas , 1995, International journal of cancer.
[8] Erich A. Nigg,et al. Cellular substrates of p34cdc2 and its companion cyclin-dependent kinases , 1993 .
[9] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[10] B. Franza,et al. cdc2 phosphorylation is required for its interaction with cyclin. , 1991 .
[11] Herman Yeger,et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.
[12] Emma Lees,et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.
[13] Peter A. Jones,et al. P16 gene in uncultured tumours , 1994, Nature.
[14] E. Harlow,et al. Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.
[15] S H Kim,et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Loda,et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.
[17] H. Yokozaki,et al. Overexpression of Cyclin‐dependent Kinase‐activating CDC25B Phosphatase in Human Gastric Carcinomas , 1997, Japanese journal of cancer research : Gann.
[18] C. Boshoff,et al. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1 , 1997, Journal of virology.
[19] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[20] S. Matsushita,et al. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. , 1984, Science.
[21] Stephen J. Elledge,et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.
[22] R. Weinberg,et al. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. , 1994, Genes & development.
[23] S H Kim,et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.
[24] R. Bernards,et al. CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.
[25] M. Ogawa,et al. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. , 1994, Biochemical and biophysical research communications.
[26] A. Iolascon,et al. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. , 1996, Leukemia.
[27] H. Yokozaki,et al. Frequent Amplification of the Cyclin E Gene in Human Gastric Carcinomas , 1995, Japanese journal of cancer research : Gann.
[28] S. Reed,et al. Cyclin E-induced S phase without activation of the pRb/E2F pathway. , 1997, Genes & development.
[29] Y. Xiong,et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. , 1994, Oncogene.
[30] L Meijer,et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.
[31] Carl W. Miller,et al. Alterations of CDKN2 (p16) in non‐small cell lung cancer , 1995, Genes, chromosomes & cancer.
[32] J. Ahomadégbé,et al. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417. , 1989, Biochemical pharmacology.
[33] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[34] K. Kinzler,et al. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.
[35] S. Hinrichs,et al. Structural evidence for the authenticity of the human retinoblastoma gene. , 1987, Science.
[36] R. Weinberg,et al. A cyclin associated with the CDK-activating kinase MO15 , 1994, Nature.
[37] L. Hartwell,et al. Checkpoints: controls that ensure the order of cell cycle events. , 1989, Science.
[38] Steven K. Hanks,et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.
[39] A. Arnold. The cyclin D1/PRAD1 oncogene in human neoplasia. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[40] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[41] Seung Ki Lee,et al. A Specific Inhibitor of Cyclin-dependent Protein Kinases, CDC2 and CDK2 , 1996, Molecules and Cells.
[42] Marc W. Kirschner,et al. How Proteolysis Drives the Cell Cycle , 1996, Science.
[43] D. Demetrick,et al. Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. , 1994, Cytogenetics and cell genetics.
[44] S. Kaufmann,et al. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. , 1996, Cancer research.
[45] M. Barinaga. A new twist to the cell cycle. , 1995, Science.
[46] E. Sausville,et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.
[47] A. Rustgi,et al. p16 inhibition of transformed and primary squamous epithelial cells. , 1996, Oncogene.
[48] C. Bréchot,et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma , 1990, Nature.
[49] S. Mori,et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. , 1994, Cancer research.
[50] Marc W. Kirschner,et al. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2 , 1991, Cell.
[51] David M. Livingston,et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.
[52] M. Merino,et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.
[53] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[54] L Meijer,et al. Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.
[55] Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1 , 1997, Current Biology.
[56] A. N. Meyer,et al. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Giordano,et al. A Unique Domain of pRb2/p130 Acts as an Inhibitor of Cdk2 Kinase Activity* , 1997, The Journal of Biological Chemistry.
[58] Jiri Bartek,et al. Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.
[59] R. Weinberg,et al. Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[60] W. Lee,et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence , 1987, Science.
[61] R. Eddy,et al. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. , 1989, The Journal of clinical investigation.
[62] A. Harris,et al. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. , 1995, Journal of cell science.
[63] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[64] A. Kumagai,et al. Purification and Molecular Cloning of Plx1, a Cdc25-Regulatory Kinase from Xenopus Egg Extracts , 1996, Science.
[65] James M. Roberts,et al. Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.
[66] N. Saijo,et al. Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. , 1994, Biochemical and biophysical research communications.
[67] S. Reed,et al. Isolation of three novel human cyclins by rescue of G1 cyclin (cln) function in yeast , 1991, Cell.
[68] James M. Roberts,et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.
[69] J. Bartek,et al. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase) , 1994, The Journal of cell biology.
[70] R. Eeles,et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. , 1995, The American journal of pathology.
[71] G. Landberg,et al. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein , 1997, Oncogene.
[72] S. Lelièvre,et al. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[73] R. Maestro,et al. Overexpression of CDC25A and CDC25B in head and neck cancers. , 1997, Cancer research.
[74] Sung-Hou Kim,et al. Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.
[75] A Joly,et al. CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation* , 1997, The Journal of Biological Chemistry.
[76] E. Karsenti,et al. Activation of the phosphatase activity of human cdc25A by a cdk2‐cyclin E dependent phosphorylation at the G1/S transition. , 1994, The EMBO journal.
[77] R. Naik,et al. An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis , 1988 .
[78] K. Kinzler,et al. Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.
[79] S. Freer,et al. Design of enzyme inhibitors using iterative protein crystallographic analysis. , 1991, Journal of medicinal chemistry.
[80] A. Look,et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. , 1993, Cancer research.
[81] C. Sheehan,et al. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma , 1997, Cancer.
[82] R. Zeillinger,et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.
[83] B. Dynlacht,et al. Specific regulation of E2F family members by cyclin-dependent kinases , 1997, Molecular and cellular biology.
[84] P. Jeffrey,et al. Structural basis of cyclin-dependent kinase activation by phosphorylation , 1996, Nature Structural Biology.
[85] K Nasmyth,et al. Viewpoint: Putting the Cell Cycle in Order , 1996, Science.
[86] J. Bartek,et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.
[87] R. DuBois,et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. , 1997, Cancer research.
[88] M. Gossen,et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. , 1994, Molecular and cellular biology.
[89] D. Beach,et al. Activation of cdc2 protein kinase during mitosis in human cells: Cell cycle-dependent phosphorylation and subunit rearrangement , 1988, Cell.
[90] L. Meijer,et al. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. , 1997, Experimental cell research.
[91] K. Kinzler,et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.
[92] Tony Hunter,et al. Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2 , 1989, Cell.
[93] P. Nurse. Regulation of the eukaryotic cell cycle. , 1997, European journal of cancer.
[94] F. C. Lucibello,et al. Inducible acceleration of G1 progression through tetracycline-regulated expression of human cyclin E. , 1994, Oncogene.
[95] G. Kong,et al. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. , 1997, British Journal of Cancer.
[96] L. Hillis,et al. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. , 1988, The New England journal of medicine.
[97] Daniel A. Gschwend,et al. Molecular docking towards drug discovery , 1996, Journal of molecular recognition : JMR.
[98] D. Bortner,et al. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.
[99] Amanda G Paulovich,et al. When Checkpoints Fail , 1997, Cell.
[100] E. Sausville,et al. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[101] James M. Roberts,et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. , 1996, Genes & development.
[102] M. Loda,et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.
[103] M. Pagano,et al. Cell cycle regulation by the ubiquitin pathway , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] S. Hiebert. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression , 1993, Molecular and cellular biology.
[105] R. Hruban,et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.
[106] G. Landberg,et al. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. , 1996, British Journal of Cancer.
[107] Ernest D. Laue,et al. Structure of the cyclin-dependent kinase inhibitor p19Ink4d , 1997, Nature.
[108] L. Meijer,et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. , 1997, Journal of medicinal chemistry.
[109] E. Sugikawa,et al. Inhibition of p53 Protein Phosphorylation by 9‐Hydroxyellipticine: A Possible Anticancer Mechanism , 1995, Japanese journal of cancer research : Gann.
[110] H. Sedlacek,et al. Antitumoral activity of flavone L-86-8275. , 1995, International journal of oncology.
[111] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[112] E. Nabel,et al. The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo , 1995, Nature Medicine.
[113] K. G. Coleman,et al. Identification of CDK4 Sequences Involved in Cyclin D1 and p16 Binding* , 1997, The Journal of Biological Chemistry.
[114] K. A. McKenna,et al. Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-converting enzyme-related proteases. , 1996, Cancer research.
[115] S. van den Heuvel,et al. Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.
[116] S. Elledge,et al. G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts , 1998, Current Biology.
[117] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[118] P. Hajduk,et al. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. , 1997, Journal of medicinal chemistry.
[119] C. Moskaluk,et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.
[120] P. Pollock,et al. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds , 1997, Oncogene.
[121] A. El‐Naggar,et al. PRAD‐1 (CCND1)/Cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma , 1994, Cancer.
[122] David O. Morgan,et al. Principles of CDK regulation , 1995, Nature.
[123] J. Takahara,et al. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. , 1996, Biochemical and biophysical research communications.
[124] E. Sausville,et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.
[125] T. Hunter,et al. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.
[126] Tony Hunter,et al. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.
[127] Andrew W. Murray,et al. Cyclin synthesis drives the early embryonic cell cycle , 1989, Nature.
[128] E. Schierenberg,et al. Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases , 1995, Biology of the cell.
[129] A. Pardee,et al. A restriction point for control of normal animal cell proliferation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[130] Bruno Amati,et al. Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.
[131] K. Keyomarsi,et al. Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[132] S. Kaufmann,et al. Antineoplastic Agents: the Importance of Sequence of Administration' , 2022 .
[133] R. Fåhraeus,et al. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide from p16CDKN2/INK4A , 1996, Current Biology.
[134] J. Lapointe,et al. A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.
[135] M. Ewen,et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.
[136] C. Sherr. Cancer Cell Cycles , 1996, Science.
[137] H. Yokozaki,et al. Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas , 1993, International journal of cancer.
[138] M. Kitagawa,et al. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. , 1994, Oncogene.
[139] J. Nevins,et al. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. , 1992, Science.
[140] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[141] R. Kerbel,et al. Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.
[142] W. Ryder,et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. , 1996, British Journal of Cancer.
[143] Stephen J. Elledge,et al. Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.
[144] J. Bartek,et al. Cell cycle‐related variation and tissue‐restricted expression of human cyclin D1 protein , 1994, The Journal of pathology.
[145] A. Okuyama,et al. MAP4 is the in vivo substrate for CDC2 kinase in HeLa cells: identification of an M-phase specific and a cell cycle-independent phosphorylation site in MAP4. , 1997, Biochemistry.
[146] W. Zhou,et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. , 1994, Cancer research.
[147] D. Beach,et al. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. , 1995, Genes & development.
[148] Stephen J. Elledge,et al. Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.
[149] P. Nowell,et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. , 1984, Science.
[150] James M. Roberts,et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.
[151] E. Lees,et al. Cyclin E, a potential prognostic marker for breast cancer. , 1994, Cancer research.
[152] Bert Vogelstein,et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 , 1996, Nature.
[153] E. Sausville,et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.
[154] P. Anderson,et al. Kinase cascades regulating entry into apoptosis , 1997, Microbiology and molecular biology reviews : MMBR.
[155] H. Nguyen,et al. Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. , 1995, Oncogene.
[156] J. Slingerland,et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. , 1995, Oncogene.
[157] R. Weinberg,et al. Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.
[158] P. Nurse,et al. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. , 1991, The EMBO journal.
[159] Y. Shibata,et al. p53-independent induction of apoptosis by cyclin-dependent kinase inhibition. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[160] D. Fisher. Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.
[161] D. Sidransky,et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.
[162] J. Blow,et al. Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.
[163] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[164] James M. Roberts,et al. Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.
[165] Philip D. Jeffrey,et al. Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex , 1996, Nature.
[166] P. Beer-Romero,et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.
[167] P. Wipf,et al. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. , 1997, Biochemistry.
[168] M. Sporn,et al. Recent advances in chemoprevention of cancer. , 1997, Science.
[169] X. Liu,et al. G1 control gene status is frequently altered in resectable non‐small cell lung cancer , 1997, International journal of cancer.
[170] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[171] J. Leiden,et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. , 1995, The Journal of clinical investigation.
[172] M. Loda,et al. CDC25 phosphatases as potential human oncogenes. , 1995, Science.
[173] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[174] Stephen H. Friend,et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.
[175] M. Nagasawa,et al. Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation. , 1997, Journal of immunology.
[176] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[177] J. Gibbs,et al. Pharmaceutical research in molecular oncology , 1994, Cell.
[178] S. Shousha,et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.